Glaxo Tries to Shake Marketing Questions on Advair – Wall Street Journal


Wall Street Journal

Glaxo Tries to Shake Marketing Questions on Advair
Wall Street Journal
GlaxoSmithKline's $3 billion criminal and civil settlement with the U.S. government this week raises questions about the future of asthma treatment Advair.
Glaxo Executives Cited in Case Now Lead Sanofi, ActelionBusinessweek
WSJ: Glaxo Tries to Shake Marketing QuestionsNASDAQ
Ex-Glaxo execs in U.S. case now lead other drugmakersBend Bulletin
FiercePharma –NPR (blog)
all 46 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.